A novel nomogram for predicting cancer-specific survival in women with uterine sarcoma: a large population-based study

Yuan-jie Li1†, Jun Lyu2†, Chen Li3, Hai-rong He4, Jin-feng Wang3, Yue-ling Wang3, Jing Fang3 and Jing Ji3*

Abstract

Background: Uterine sarcoma (US) is a rare malignant uterine tumor with aggressive behavior and rapid progression. The incidence of US ranges from 1.55 to 1.95 per 100,000 women per year [2]. The current classification of US includes endometrial stromal sarcoma, leiomyosarcoma, and mixed epithelial and mesenchymal tumors according to the common histological types [3]. No common etiology has been identified, but several agents might be associated with US, such as tamoxifen treatment, pelvic radiation therapy, and hereditary leiomyomatosis [4]. Management involves coordinating...
multidisciplinary treatment including surgery, radiotherapy, chemotherapy and hormonal blockade. However, the 5-year survival rate is less than 50% in early stages and less than 15% in advanced stages [5, 6].

The American Joint Committee on Cancer (AJCC) staging system is the most extensively used clinical tool in determining the prognosis of cancer [7] and it is based on the tumor (T), number of metastatic lymph nodes (N), and distant metastasis (M). However, US is a very heterogeneous disease. The patient response to therapy differs widely, and the survival rate varies within the same stage. Some clinical characteristics, such as age, race, and tumor size, are noteworthy factors influencing the individual survival outcomes of cancer patients [8, 9]. For example, US is twice as frequent among black women than among white women, and the risk of sarcoma is higher among women aged over 50 years [10]. Thus, a novel, more accurate prognostic tool that includes personalized characteristics is necessary to improve the accuracy of prognosis among women with US.

Nomograms presented by graphs have become widely used to predict the outcome of malignant tumors. This study aimed to develop an effective nomogram to predict the cancer-specific survival (CSS) of US patients based on a cohort from the SEER database to help guide individual treatment decisions for US patients.

**Methods**

**Study design and data source**

This is a retrospective population-based study of the data from patients diagnosed with US between 2010 and 2015, obtained from the SEER database. The SEER data are registered cases of cancer from throughout the USA.

All of the related information was derived from the SEER program (the latest version covering 18 registries with additional chemotherapy data) by using SEER*Stat version 8.3.6.1 [https://seer.cancer.gov/] [11–13]. The population included in this study was patients diagnosed with uterine sarcoma between 2010 and 2015, with the ICD-O-3 morphology codes [10] 8800/3–8805/3; 8890/3, 8891/3, 8896/3; 8933/3; 8930/3, 8931/3, 8935/3; 8950/3, 8951/3, and 8980/3. We initially excluded other morphological US and selected 3,922 female patients between 2010 and 2015.

**Data collection**

Demographic and clinicopathological features were extracted from SEER, including race, age at diagnosis, marital status, tumor size, pathology grade, SEER stage, AJCC stage, surgery, chemotherapy, and radiotherapy. We noticed that the summary stage in the SEER database had four levels: in situ, localized, regional, and distant. In our study, we only included the last three levels due to the lack of patient data for the in situ category. Tumor pathology grade was divided into four levels according to the degree of differentiation: Grade I (well), II (moderately), III (poorly), and IV (undifferentiated or anaplastic) [12]. The tumor size was classified as ≤50 mm, >50 mm and unknown. Based on the SEER database, surgery status was divided into two groups: “Yes” means surgery performed, while “No” means no surgery performed due to three situations as follows: not recommended, recommended but the patient refused or died before surgery. Radiotherapy status was also classified: “Yes” means any type of radiation performed, including radioactive implants, beam radiation, or a combination of beams with implants or isotopes [12], while “No” means none/unknown, refused, or recommended but unknown if administered. Chemotherapy status was classified as follows: “Yes” means chemotherapy performed, and “No” means not performed or unknown. The endpoint of this study was death of the patients due to US. We excluded one patient who was found to have no tumor, as well as those who had an unknown insurance record (n = 60).

**Criteria for data selection**

The exclusion criteria were follows: (1) patients with no confirmation by microscopy or only on autopsy; (2) no tumor found; and (3) unknown insurance status. This retrospective study initially identified 3922 uterine sarcoma patients enrolled in the SEER database from 2010 to 2015, among which 3861 patients were finally included based on the criteria mentioned above (Fig. 1).

**Statistical analysis**

Twelve pathological and clinical features that we mentioned above were applied to conduct the analyses. All of the selected patients were randomly divided into a training cohort (n = 2702) and a validation cohort (n = 1159) at a ratio of 7:3 for nomogram construction. Continuous variables are presented as medians with interquartile ranges, while categorical variables are presented as numbers with percentages. The distributions of the characteristics between the training and validation cohort sets were compared using the \( \chi^2 \) test. Variables with statistical significance in the univariate analysis were entered into multivariate regression analysis. Cox regression was developed to assess the effects of correlation factors (\( p = 0.1 \)). Then, we established a nomogram that predicted the 1-, 3-, and 5-year CSS of US. The differentiation ability of the nomogram was evaluated using the C-index and the area under the time-dependent receiver operating characteristic (ROC) curve. A C-index value of 0.5 indicated no predictive power, and a C-index of 1.0 indicated complete differentiation. We compared the accuracy and comprehensiveness of our nomogram with
the AJCC stage by using net reclassification improvement (NRI) and integrated discrimination improvement (IDI) [14]. The consistency of the survival probabilities predicted by the nomogram with the actual situation was assessed by calibration curves, and the clinical validity of the nomogram was tested via DCA [15].

All statistical analyses and graphics were performed with R software (version 3.6.0; http://www.Rproject.org) and SPSS software (version 24.0, SPSS, Chicago, IL, USA), with \( P < 0.05 \) considered to indicate statistical significance.

Results

Patient characteristics

A total of 3861 US patients extracted from the SEER database were randomly divided into a training cohort (\( n = 2702 \)) and a validation cohort (\( n = 1159 \)) at a ratio of 7:3. The median age at diagnosis in the training and validation cohorts was 62 (interquartile range, 53–69 years) and 60 (interquartile range, 51–69 years), respectively. The majority of the patients were white (69.2 and 71.2%), married (47.6 and 48.3%), and insured (95.4 and 96.3%). Most of the tumors were of pathological grade III or IV and larger than 50 mm in both cohorts. Nearly half of the patients were histologically diagnosed with carcinosarcoma. The distribution of different SEER stages was very similar between the groups, with a slightly higher rate in the localized group (37.4 and 42.5%). Nearly half of the patients were in AJCC stage I (41.0 and 45.1%) and less than one tenth were in AJCC stage II (9.7 and 8.1%). Most of the patients received surgery (90.8 and 92.4%), with a few receiving radiotherapy and over half receiving chemotherapy in both cohorts.

A summary of these clinical characteristics is given in Table 1.

Variable screening and multivariate cox regression analysis results

According to the Cox stepwise regression analysis, tumor primary site, years of diagnosis and surgery site were excluded from further study due to no difference in the prognosis for US patients. Multivariate Cox regression analyses demonstrated that age at diagnosis [hazard ratio (HR) = 1.0116, \( p < 0.001 \)], being black (HR = 1.1698, \( p < 0.05 \)), single (HR = 1.2181 vs. married, \( p < 0.05 \)), SDW (HR = 1.2965 vs. married, \( p < 0.001 \)), tumor size (> 50 mm, HR = 1.4861 vs. \( \leq \) 50 mm, \( p < 0.001 \); tumor size unknown, HR = 1.3345, \( p < 0.01 \)), higher pathology grade (Grade III, HR = 7.3773 vs. pathology grade I, \( p < 0.001 \); IV, HR = 7.0185, \( p < 0.001 \)), SEER stage (regional, HR = 1.8809 vs. localized, \( p < 0.001 \); distant, HR = 2.5199, \( p < 0.001 \)), and higher AJCC stage (III, HR = 1.7459 vs. AJCC stage I, \( p < 0.001 \); IV, HR = 2.2275, \( p < 0.001 \)) were all
independent risk factors. Meanwhile, we found that leiomyosarcoma (HR = 0.655 vs. sarcoma, p < 0.01), carcinosarcoma (HR = 0.6099 vs. sarcoma, p < 0.01), insurance (no insurance HR = 1.4851, p < 0.01), receiving surgery (no/unknown HR = 2.7559, p < 0.001), adjuvant radiotherapy (no/unknown HR = 1.3267, p < 0.001), and adjuvant chemotherapy (no/unknown HR = 1.5355, p < 0.001) were protective factors for surviving US. These results also indicated that other races, marital status, pathology grade II, adenosarcoma, stromal sarcoma and AJCC stage II were not significant risk factors (P > 0.05). The results of the multivariate Cox regression analysis are presented in Table 2.

### Table 1: Patient characteristics in the study

| Variable                     | Training cohort (n = 2702) | Validation cohort (n = 1159) |
|------------------------------|----------------------------|-----------------------------|
| Medium age at diagnosis,     | 62 (53–69)                 | 60 (51–69)                  |
| (25th–75th percentile)       |                            |                             |
| Race n (%)                   |                            |                             |
| White                        | 1869 (69.2)                | 808 (71.2)                  |
| Black                        | 591 (22.1)                 | 243 (20.2)                  |
| Other                        | 242 (8.6)                  | 108 (8.6)                   |
| Marital status n (%)         |                            |                             |
| Married                      | 1257 (47.6)                | 561 (48.3)                  |
| Single                       | 586 (22.3)                 | 261 (22.7)                  |
| SDW                          | 736 (25.6)                 | 293 (25.5)                  |
| Unknown                      | 123 (4.6)                  | 44 (3.5)                    |
| Insurance record n (%)       |                            |                             |
| Yes                          | 2584 (95.4)                | 1117 (96.3)                 |
| No                           | 118 (4.6)                  | 42 (3.7)                    |
| Tumor size n (%)             |                            |                             |
| ≤ 50 mm                      | 710 (23.1)                 | 313 (23.8)                  |
| > 50 mm                      | 1596 (61.4)                | 677 (61.6)                  |
| Unknown                      | 396 (13.6)                 | 169 (14.6)                  |
| Pathological grade n (%)     |                            |                             |
| I                            | 169 (6.4)                  | 76 (6.0)                    |
| II                           | 345 (12.6)                 | 135 (11.4)                  |
| III                          | 1193 (43.0)                | 527 (44.5)                  |
| IV                           | 995 (38.7)                 | 421 (38.2)                  |
| Histological type n (%)      |                            |                             |
| Sarcoma                      | 76 (4.3)                   | 20 (2.8)                    |
| Leiomyosarcoma               | 532 (28.3)                 | 215 (26.6)                  |
| Adenosarcoma                 | 124 (4.4)                  | 45 (3.8)                    |
| Stromal sarcoma              | 455 (14.1)                 | 207 (15.5)                  |
| Carcinosarcoma               | 1515 (48.8)                | 672 (51.3)                  |
| SEER stage n (%)             |                            |                             |
| Localized                    | 1116 (37.4)                | 537 (42.5)                  |
| Regional                     | 825 (29.1)                 | 321 (28.2)                  |
| Distant                      | 761 (33.5)                 | 301 (28.3)                  |
| AJCC stage n (%)             |                            |                             |
| I                            | 1225 (41.0)                | 573 (45.1)                  |
| II                           | 236 (7.9)                  | 84 (6.8)                    |
| III                          | 572 (20.0)                 | 222 (18.6)                  |
| IV                           | 669 (23.2)                 | 280 (23.6)                  |
| Surgery status n (%)         |                            |                             |
| Yes                          | 2516 (90.8)                | 1090 (92.4)                 |
| No/unknown                   | 186 (9.2)                  | 69 (8.6)                    |
| Radiotherapy status n (%)    |                            |                             |
| Yes                          | 782 (26.3)                 | 313 (24.6)                  |
| No/unknown                   | 1920 (73.7)                | 846 (75.4)                  |
| Chemotherapy status n (%)    |                            |                             |
| Yes                          | 1420 (52.4)                | 598 (53.2)                  |
| No/unknown                   | 1282 (47.6)                | 561 (46.8)                  |

### Nomogram construction

A nomogram was constructed for predicting the 1-, 3-, and 5-year CSS based on the multivariate Cox regression analysis (Fig. 2). The pathological grade was set as a reference scale ranging from 0 to 100 because it had the largest coefficient absolute value. The probabilities of 1-, 3- and 5-year CSS could be easily calculated by adding the point value of each variable. As shown in Fig. 2, the pathological grade had the strongest influence on CSS, followed by age at diagnosis, surgery status, SEER stage, AJCC stage, histological grade, chemotherapy, insurance record, tumor size, race, radiotherapy, and marital status.

### Nomogram comparison and evaluation

The C-indices in both the training and validation cohorts were higher than those of the AJCC 7th edition staging system (0.796 vs. 0.706, 0.767 vs. 0.713), indicating that our new model showed better discriminative ability. Furthermore, the AUCs of the training cohort for the 1-, 3- and 5-year CSS were significantly larger (0.842, 0.845, and 0.860, respectively) than those of the traditional system (0.755, 0.772, and 0.774, respectively). Likewise, the ROC values were also significantly larger (0.833, 0.798, and 0.797 at 1-, 3-, and 5-year vs. 0.763, 0.741, and 0.747, respectively) (Fig. 3).

### Validation and calibration of the nomogram

The NRI values for the 1-, 3- and 5-year CSS rates in the training cohort were 64.6% (95% confidence interval [CI] = 55.3–73.5%), 59.0% (95% CI = 50.7–67.9%) and 62.2% (95% CI = 52.8–71.4%), respectively, and in the validation cohort, they were 47.2% (95% CI = 25.0–63.1%), 37.6% (95% CI = 14.1–51.4%) and 29.9% (95% CI = 7.4–55.0%), respectively. Moreover, the IDI values for the 1-, 3- and 5-year CSS rates in the training cohort were 8.64, 9.63 and 9.50%, respectively, and 3.98, 5.79 and 5.88% in the validation cohort (all p < 0.001). These results all indicated that the nomogram predicted survival with greater accuracy than the AJCC model.
Calibration plots predicting the 1-, 3- and 5-year CSS for the training and validation cohorts were nearly identical to the practical observations, which demonstrated that the new model had excellent calibration ability (Fig. 4).

Clinical usefulness

Finally, a DCA curve was used to evaluate the clinical usability and benefits of the nomogram. Compared to the AJCC staging system, all of the DCA curves showed larger net benefits of the new model in both the training and validation cohorts (Fig. 5). These results demonstrated that the new model had better clinical benefits than the AJCC staging system.

Discussion

Uterine sarcoma is a group of rare malignant mesenchymal tumors with various histologic types and aggressive progression and a poor prognosis [3]. To date, there is no efficient prognostic staging system that could help to estimate CSS at diagnosis for US patients.

A nomogram is a statistical tool that can provide accurate predictions for malignant tumors through a simple graphical presentation. A nomogram could provide accurate individualized predictions based on specified data points. Recently, nomograms have been developed for several cancers, such as NSCLC hepatocellular carcinoma (HCC), and adult skin melanoma [16–18]. However, few nomograms have been constructed for US patients. Zhou et al. [19] identified a 6-gene-based prognostic signature for US. Li et al. [20] evaluated the benefit of adjuvant radiotherapy for uterine leiomyosarcoma and carcinosarcoma. The latest and largest study performed by Mona Hosh et al. [10] identified 13,089 cases of uterine sarcoma diagnosed from 2000 to 2012. To our knowledge, this study was the first to develop a comprehensive prognostic nomogram to predict the 1-, 3-, and 5-year CSS for US based on the SEER database.

Pathological grade, age at diagnosis, surgery, AJCC stage, SEER stage, histological differentiation, chemotherapy, insurance record, tumor size, ethnicity, radiotherapy and marital status were identified as prognostic factors of CSS through multivariate Cox regression. Among them, the most notable factor affecting the CSS of US patients is pathological grade. The survival rates of patients with grades III and IV were worse than those of grade I patients, consistent with previous studies [21]. However, there were no significant differences between patients with grade III and grade IV disease.

Age at diagnosis had secondary crucial role in our model, although the exact mechanism remains unclear. Mona Hosh et al. [10] also found that the incidence of US increased with increasing age, and patients aged

Table 2

| Variable                      | Hazard ratio | 95% CI       | p value |
|-------------------------------|--------------|--------------|---------|
| Age at diagnosis              | 1.0116       | 1.0061–1.0172| <0.001***|
| Race                          |              |              |         |
| White                         | Reference    |              |         |
| Black                         | 1.1698       | 1.0225–1.3383| 0.02**  |
| Other                         | 0.8481       | 0.6698–1.0739| 0.171   |
| Marital status                |              |              |         |
| Married                       | Reference    |              |         |
| Single                        | 1.2181       | 1.0436–1.4217| 0.012*  |
| SDW                           | 1.2965       | 1.1230–1.4969| <0.001***|
| Other                         | 1.2816       | 0.9740–1.6863| 0.076   |
| Insurance record              |              |              |         |
| Yes                           | 1.4851       | 1.1367–1.9404| 0.004** |
| No                            | Reference    |              |         |
| Tumor size                    |              |              |         |
| ≤ 50 mm                       | Reference    |              |         |
| > 50 mm                       | 1.4861       | 1.2674–1.7425| <0.001***|
| Unknown                       | 1.3345       | 1.0802–1.6487| 0.007** |
| Pathological grade            |              |              |         |
| I                             | Reference    |              |         |
| II                            | 1.3135       | 0.7662–2.518 | 0.321   |
| III                           | 7.3773       | 4.5441–11.977| <0.001***|
| IV                            | 7.0185       | 4.3528–11.316| <0.001***|
| Histological type             |              |              |         |
| Sarcoma                       | Reference    |              |         |
| Leiomyosarcoma                | 0.6550       | 0.4839–0.8866| 0.006** |
| Adenosarcoma                  | 0.6288       | 0.3919–1.0089| 0.054   |
| Stromal sarcoma               | 0.9274       | 0.6623–1.2984| 0.661   |
| Carcinosarcoma                | 0.6099       | 0.4535–0.8202| 0.001** |
| SEER stage                    |              |              |         |
| Localized                     | Reference    |              |         |
| Regional                      | 1.8809       | 1.3831–2.5580| <0.001***|
| Distant                       | 2.5199       | 1.6708–3.8005| <0.001***|
| AJCC stage                    |              |              |         |
| I                             | Reference    |              |         |
| II                            | 1.0136       | 0.7096–1.4478| 0.941   |
| III                           | 1.7459       | 1.2843–2.3735| <0.001***|
| IV                            | 2.2275       | 1.4818–3.3484| <0.001***|
| Surgery status                |              |              |         |
| Yes                           | Reference    |              |         |
| No/unknown                    | 2.7559       | 2.2503–3.375 | <0.001***|
| Radiotherapy status           |              |              |         |
| Yes                           | Reference    |              |         |
| No/unknown                    | 1.3267       | 1.1567–1.5216| <0.001***|
| Chemotherapy status           |              |              |         |
| Yes                           | Reference    |              |         |
| No/unknown                    | 1.5355       | 1.3509–1.7453| <0.001***|

SDW: Separated, divorced, and widowed, SEER: Surveillance, Epidemiology, and End Results, HR: hazard ratio, AJCC: American Joint Committee on cancer

*p < 0.05, **p < 0.01, ***p < 0.001
50 years or older had worse survival than younger patients. The present study indicated that black US patients, tumor size (> 5.0 cm) and histological type were all associated with a poor prognosis for patients with US. Other studies also found that progression and poor survival rates were more common in patients who were black, had carcinosarcoma, or had larger tumors [22].

More interestingly, we discovered for the first time that marital status influenced the CSS of uterine sarcoma. Previous studies have shown that unmarried patients exhibit shorter OS and CSS than married patients with lung and liver cancer [23, 24]. In the present study, patients who were separated, divorced or widowed (SDW) had worse survival compared to married patients, followed by single patients. Marriage can not only provide financial support, but also relieve depression and anxiety among patients with cancer [25]. A spouse might influence the patients’ behavior, such as encouraging them to quit smoking and excessive alcohol drinking. Married patients are also more likely to accept more aggressive treatment and participate in regular follow-up. Thus, married patients would have better social support and better financial support, leading to a relatively better psychological state. Insurance was also strongly associated with the prognosis of uterine sarcoma. Patients with insurance could receive better medical support, be less economical and have
Fig. 3 ROC curve analyses were generated to test the performance evaluation between the new model and the traditional AJCC model, by the AUC. A, B and C came from the training set, and D, E, and F came from the validation set.

Fig. 4 Calibration curves for 1-, 3- and 5-year CSS depict the calibration of each model in terms of the agreement between the predicted probabilities and observed outcomes of the training cohort (A, C, E) and validation cohort (B, D, F).
less psychological distress than uninsured patients. This new information could help clinicians make more effective clinical decisions.

In addition, we also found that surgery status, SEER stage, AJCC stage and radiotherapy status affected the survival probability of US. Surgery is the gold standard treatment for US [2]. In addition, among these clinical parameters, the surgery status had the highest discriminating power in our study. Another important factor was the localized stage of US at initial diagnosis. Patients with metastatic disease at diagnosis had more aggressive disease than those with localized disease.

Radiation therapy is usually performed for advanced uterine sarcoma patients. Several retrospective studies suggested that radiotherapy after surgery could decrease pelvic recurrence, but not distant metastases [26]. Wong et al. [27] found that adjuvant pelvic radiotherapy might improve OS and reduce local recurrence for leiomyosarcoma. In our study, Fig. 2 clearly shows that both surgery and radiotherapy could improve survival based on the 1-, 3-, and 5-year CSS probabilities among US patients.

Notably, we identified for the first time that chemotherapy provides patients with a better prognosis. There are very few studies focusing on chemotherapy and patient prognosis for US patients in the SEER database. Efficacious chemotherapy to achieve prolonged survival in those with both early and advanced-stage US has been elusive. Hensley et al. [28] evaluated the role of 4 cycles of gemcitabine and docetaxel in 25 high-grade uterine leiomyosarcoma patients, and found prolonged PFS and OS. However, Littell et al. [29] compared gemcitabine-docetaxel with observation among 110 stage I uterine leiomyosarcoma (uLMS) patients after surgery, and found no significant difference in disease-free survival, OS or recurrence between the two groups. Our nomogram showed that chemotherapy had an even higher discriminatory power than radiotherapy. These data on chemotherapy could help clinicians choose individualized adjuvant treatment after surgery.

NRI, IDI, DCA, discrimination and calibration were used to evaluate the performance of the nomogram and to compare it with TNM-based AJCC staging. The survival nomogram showed better discrimination with C-indices of 0.796, and 0.767 for the training and validation cohorts, respectively, as the values were only 0.706 and 0.713 for the AJCC stage. As shown in Fig. 3, the 1-, 3-, and 5-year AUC values of the AJCC staging system were significantly lower than those of the nomogram. The plots resembling 45-degree lines indicated that the predictions of our nomogram were well-calibrated. Furthermore, the NRI and IDI both demonstrated that the new nomogram improved the predictive ability compared with the AJCC staging system. Finally, DCA curves were used to assess the clinical effectiveness of the nomogram. Our results showed that the 1-, 3-, and 5-year DCA curves for CSS exhibited better clinical effectiveness for predicting survival than the traditional AJCC staging system in both the training and validation cohorts.

This study, of course, still had several limitations. First, adjuvant hormonal therapy was not included.
in this nomogram, which might be because hormonal therapy is not routinely recommended as postoperative treatment in all histological types of US. Second, the SEER database did not use the FIGO staging system for US patients; instead, the SEER stage and AJCC stage were used. Third, some potential predictive variables, such as serum markers and neutrophil-to-lymphocyte ratios, were not included in this study because of the absence of these data absence in the SEER database. Fourth, our study excluded patients diagnosed after 2015. The NCCN guideline for uterine neoplasms has modified the pathology types of uterine sarcoma since 2016. More recently, diagnosed patients and patients with several rare pathological types were excluded to ensure sufficient follow-up so that we could adequately assess the association of treatment with survival.

Conclusions
In summary, we have established a novel nomogram to predict the 1-, 3-, and 5-year CSS for US based on the SEER database. Our nomogram could be used as a valuable and effective tool to help clinicians to provide more individualized treatment and individualized survival prediction in clinical practice.

Abbreviations
US: Uterine sarcoma; CSS: Cancer-specific survival; AJCC: American Joint Committee on Cancer; SEER: Surveillance, Epidemiology, and End Results database; SDW: Separated, Divorced and Widowed; C-index: Concordance index; AUC: Area under the curve; NRI: Net reclassification improvement; IDI: Integrated discrimination improvement; DCA: Decision-curve analysis; HR: Hazard ratio; ICD-O-3: International Classification of Diseases for Oncology, third edition morphology code.

Acknowledgements
We would like to thank the SEER program for providing open access to the database.

Author contributions
LYJ and LJ contributed equally to the work; they analyzed the data and performed the conceptualization and formal analysis. LC performed statistical analysis and data interpretation. HR performed investigation, literature research. JJ designed the study and submitting manuscript. All authors contributed to writing of the manuscript and approved the final version.

Funding
The study was supported by the General projects of Key research and Development program in Natural Foundation of Shaanxi Province, China (Grant Nos. 2017SF-015, 2019SF-139). There is no any ethical/legal conflict involved in the article. For the remaining authors none were declared.

Availability of data and materials
Data from the SEER program is available for public. The data supporting the conclusions of this article are available in the Surveillance Epidemiology, and End Results (SEER) database (https://seer.cancer.gov/).

Declarations

Ethics approval and consent to participate
This data used in this study were from public database (SEER database). Approval was waived by the Research Ethic Committee at the First Affiliated Hospital of Xi’an Jiaotong University, as SEER data is publicly available and de-identified. All methods were performed in accordance with the relevant guidelines and regulations.

Consent for publication
Not applicable.

Competing interests
All authors declare that they have no competing interests.

Author details
1 Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Xi’an Jiao Tong University Health Science Center, Xi’an, Shaanxi, China. 2 Department of Clinical Research, The First Affiliated Hospital of Jining University, Guangzhou, Guangdong, China. 3 Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China. *Department of Clinical Research Center, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China.

Received: 5 July 2021 Accepted: 11 April 2022 Published online: 14 May 2022

References
1. Albatani N, Olawaye AB, Prat J. Uterine sarcomas. Int J Gynaecol Obstet. 2018;143(Suppl. 2):S1–8. https://doi.org/10.1002/ijgo.12613.
2. Trope CG, Abeler VM, Kristensen GB. Diagnosis and treatment of sarcoma of the uterus A review. Acta Oncol. 2012;51(6):694–705. https://doi.org/10.3109/0284186X.2012.689111.
3. Rizzo A, Pantaleo MA, Saponara M, Nannini M. Current status of the adjuvant therapy in uterine sarcoma: a literature review World J Clin Cases. 2019;7(14):1753–63. https://doi.org/10.1080/21681564.2019.1660883.
4. Ganjoor KN. Uterine sarcomas. Curr Prob Cancer. 2019;43(4):283–8. https://doi.org/10.1016/j.cprobcan.2019.06.001.
5. Wu TI, Chang TC, Hsieh S, Hsu KH, Chou HH, Huang HJ, et al. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. Gynecol Oncol. 2006;100(1):166–72. https://doi.org/10.1016/j.ygyno.2005.08.010.
6. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008;112(4):820–30. https://doi.org/10.1002/cncr.23245.
7. Ami MB, Greene FL, Edge SB, Compton CC, Gershenson JD, Bookland MK, et al. The eighth edition AJCC Cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9. https://doi.org/10.3322/caac.21388.
8. Nipp R, Tramontano AC, Kong CY, Pandharipande P, Dowling EC, Schrag D, et al. Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Cancer Med. 2018;7(2):525–35. https://doi.org/10.1002/cam4.1277.
9. Doepker MP, Holt SD, Durkin MW, Chu CH, Nottingham JM. Triple-negative breast cancer: a comparison of race and survival. Am Surg. 2018;84(6):881–8.
10. Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B. Uterine sarcoma: analysis of 13,089 cases based on surveillance, epidemiology, and end results database. Int J Gynecol Cancer. 2016;26(6):1098–104. https://doi.org/10.1097/IGC.0000000000000720.
11. Surveillance Research Program, National Cancer Institute SEER*Stat software (seer.cancer.gov/seerstat) version <SEER*Stat 8.3.6.1>.
12. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Available at http://seer.cancer.gov. 2020, Assessed July 14.
13. Yang J, Li YJ, Liu QQ, Li L, Feng AZ, Wang TY, et al. Brief introduction of medical database and data mining technology in big data era. J Evid Based Med. 2020;13(1):57–69. https://doi.org/10.1111/jebm.12373.

14. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: biomarker studies. Epidemiology. 2010;21(1):128–38. https://doi.org/10.1097/EDE.0b013e3181c30fb2.

15. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565–74. https://doi.org/10.1177/0272989X06295361.

16. Grimes DA. The nomogram epidemic: resurgence of a medical relic. Ann Intern Med. 2008;149(4):273–5. https://doi.org/10.7326/0003-4819-149-4-20080819-00010.

17. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):173–80. https://doi.org/10.1016/S1470-2045(14)71116-7.

18. Chen Y, Liao F, Cao L. Web-based nomograms for predicting the prognosis of adolescent and young adult skin melanoma, a large population-based real-world analysis. Transl Cancer Res. 2020;9(11):7103–12. https://doi.org/10.21037/tcr-20-1295.

19. Zhou JG, Zhao HT, Jin SH, Tian X, Ma H. Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma. Gynecol Oncol. 2019;155(3):499–5079. https://doi.org/10.1016/j.ygyno.2019.08.033.

20. Li Y, Ren HT, Wang JM. Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study. BMC Cancer. 2019;19(1):697. https://doi.org/10.1186/s12885-019-5879-7.

21. Sait HK, Anfinan NM, Sayed ME, El Alkhayyat SS, Ghanem AT, Abayazid RM, et al. Uterine sarcoma: Clinico-pathological characteristics and outcome. Saudi Med J. 2014;35(10):1215–22.

22. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol. 2004;93(1):204–8. https://doi.org/10.1016/j.ygyno.2003.12.029.

23. Varlotto JM, McKie K, Voland RP, Flickinger JC, DeCamp MM, Maddox D, et al. The role of race and economic characteristics in the presentation and survival of patients with surgically resected non-small cell lung cancer. Front Oncol. 2018;8:146. https://doi.org/10.3389/fonc.2018.00146.

24. Wu Y, Ai Z, Xu G. Marital status and survival in patients with non-small cell lung cancer: an analysis of 7,006 patients in the SEER database. Oncotarget. 2017;8(61):103518–34. https://doi.org/10.18632/oncotarget.21568.

25. Goldzweig G, Andritsch E, Hubert A, Brenner B, Walach N, Perry S, et al. Psychological distress among male patients and male spouses: what do oncologists need to know? Ann Oncol. 2010;21(6):877–83. https://doi.org/10.1093/annonc/mdp398.

26. Champetier C, Hannoun-Levi JM, Resbeut M, Azria D, Salem N, Tessier E, et al. Postoperative radiotherapy of uterine sarcoma: a multicentric retrospective study. Cancer Radiother. 2011;15(2):89–96. https://doi.org/10.1016/j.crad.2010.05.005.

27. Wong P, Han K, Sykes J, Catton C, Lafamboise S, Fyles A, et al. Postoperative radiotherapy improves local control and survival in patients with uterine leiomyosarcoma. Radiat Oncol. 2013;24(8):128. https://doi.org/10.1186/1748-717X-8-128.

28. Hensley ML, Ishill N, Sdow R, Larkin J, Abu-Rustum N, Sabbatini R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stage I–IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol. 2009;112(3):563–7. https://doi.org/10.1016/j.ygyno.2008.11.027.

29. Littell RD, Tucker LY, Raine-Bennett T, Palen TE, Zaritsky E, Neugebauer R, et al. Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: trends and survival outcomes. Gynecol Oncol. 2017;147(1):11–7. https://doi.org/10.1016/j.ygyno.2017.07.122.